Robert Svatek, MD, highlights SWOG S1602 trial in BCG-naïve NMIBC

23 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
In the following interview, conducted at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco, California, Robert S. Svatek, MD, discussed the scientific rationale behind the SWOG S1602 trial (NCT03091660), evaluating BCG strain differences and intradermal BCG before intravesical therapy for patients with BCG-naïve non–muscle invasive bladder cancer (NMIBC).1 Svatek is a professor and the Gary and Glenda Woods President’s Distinguished University Chair in GU Oncology at UT Health San Antonio in Texas.

Editor’s Note: Svatek reports relevant disclosures with Japanese BCG laboratories, Merck, CG Oncology, Rapamycin Holdings, Emtora, and Biodexa.

REFERENCE
1. Svatek RS, Tangen C, Meeks JJ, et al. SWOG 1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer (NCT #03091660). Presented at: 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium. February 26-28, 2026. San Francisco, California. Abstract LBA629. https://meetings.asco.org/meetings/2026-asco-genitourinary-cancers-symposium/334/16917
Categoria
Oncology
Commenta per primo questo video.

Prossimo